[ad_1]
24.5
Million Covered Lives Now Eligible for Biologic Advanced Wound Care Treatment Through
Centene Corporation
Suwanee, Ga – 
Health, Inc. (OTCQB: SNWV), whose focus is the development and
commercialization of a robust and innovative advanced wound care product
portfolio for the repair and regeneration of skin, musculoskeletal tissue and vascular
structures, announced today that Centene Corporation, the largest Medicare and
Medicaid Administrator in the U.S., has included BIOVANCE® in its list of
reimbursed skin substitutes for advanced wound healing for the more than 24.5
million lives it covers. SANUWAVE, through its recent agreement with
Cellularity, Inc., is the exclusive distributor for BIOVANCE in the U.S. wound
care market.
BIOVANCE is
decellularized, dehydrated human amniotic membrane (DDHAM) that is an
intact, natural extracellular matrix (ECM) that acts as a scaffold for
restoration of functional tissue. BIOVANCE contains key ECM proteins that allow
for the migration of host cells to permeate the graft and promote tissue repair
when applied to a wound. BIOVANCE brings the progenerative power of the
amnion to tissue regeneration[i]1-6 and provides a foundation for the wound
healing process.
“Inclusion
in Centene’s list of reimbursable skin substitutes for advanced wound healing
products is a key milestone for BIOVANCE as
we continue to expand our Medicare and Medicaid access to benefit the millions
of elderly patients suffering with recalcitrant wounds,” said Ryan K. Sheffer,
Senior Director Reimbursement & Health Policy for SANUWAVE Health.
“Moving forward, we expect to increase our coverage from national payors with a
goal to gain access to the more than 250 million commercial and managed
Medicare patients, which is expected to drive BIOVANCE revenue and grow
SANUWAVE’s share in the multi-billion dollar advanced wound care market.”
About
Centene Corporation
Centene Corporation, a Fortune 100 company, is a leading
multi-national healthcare enterprise that is committed to helping people live
healthier lives. The Company takes a local approach – with local brands and
local teams – to provide fully integrated, high-quality, and cost-effective
services to government-sponsored and commercial healthcare programs, focusing
on under-insured and uninsured individuals. Centene offers affordable and
high-quality products to nearly 1 in 15 individuals across the nation,
including Medicaid and Medicare members (including Medicare Prescription Drug
Plans) as well as individuals and families served by the Health Insurance
Marketplace, the TRICARE program, and individuals in correctional facilities.
The Company also serves several international markets, and contracts with other
healthcare and commercial organizations to provide a variety of specialty
services focused on treating the whole person. Centene focuses on long-term
growth and the development of its people, systems and capabilities so that it
can better serve its members, providers, local communities, and government
partners.
About
SANUWAVE Health, Inc.
SANUWAVE
Health, Inc. (OTCQB:SNWV) (www.SANUWAVE.com) is focused on the development and
commercialization of its patented noninvasive, biological response activating
devices for the repair and regeneration of skin, musculoskeletal tissue and
vascular structures. Through its recent acquisition of Celularity’s
UltraMIST assets, SANUWAVE now combines two highly complementary and
market-cleared energy transfer technologies with two human tissue biologic
products to create a platform of scale with an end-to-end product offering in
the advanced wound care market.
SANUWAVE’s
portfolio of regenerative medicine products and product candidates activate
biologic signaling and angiogenic responses, producing new vascularization and
microcirculatory improvement, which helps restore the body’s normal healing
processes and regeneration. SANUWAVE applies its patented energy transfer
technologies in wound healing, orthopedic/spine, plastic/cosmetic and cardiac
conditions.
For
additional information about the Company, visit www.sanuwave.com.
Forward-Looking
Statements
This press
release may contain “forward-looking statements” within the meaning of the
Private Securities Litigation Reform Act of 1995, such as statements relating
to financial results and plans for future business development activities, and
are thus prospective. Forward-looking statements include all statements that
are not statements of historical fact regarding intent, belief or current
expectations of the Company, its directors or its officers. Investors are
cautioned that any such forward-looking statements are not guarantees of future
performance and involve risks and uncertainties, many of which are beyond the
Company’s ability to control. Actual results may differ materially from those
projected in the forward-looking statements. Among the key risks, assumptions
and factors that may affect operating results, performance and financial
condition are risks associated with the regulatory approval and marketing of
the Company’s product candidates and products, unproven pre-clinical and
clinical development activities, regulatory oversight, the Company’s ability to
manage its capital resource issues, competition, and the other factors
discussed in detail in the Company’s periodic filings with the Securities and
Exchange Commission. The Company undertakes no obligation to update any
forward-looking statement.
Contact:
SANUWAVE
Health, Inc.
Kevin Richardson II
Chairman and Chief Executive Officer
978-922-2447
investorrelations@sanuwave.com
Anne Marie
Fields
Managing
Director
Rx Communications
Group
afields@rxir.com
1.
Fetterolf DE, Synder RJ. Scientific and clinical support for the
use of dehydrated amniotic membrane in wound management. Wounds.
2012;24(10):299-307.
2.
Bhatia M, Pereira M, Rana H, et al. Mechanism of cell
interaction and response on decellularized human amniotic membrane:
implications in wound healing. Wounds. 2007;19(8):207-217.
3.
Faulk WP, Matthews R, Stevens PJ, et al. Human amnion as an
adjunct in wound healing. Lancet. 1980;1(8179):1156-1158.
4.
Ganatra MA. Amniotic membrane in surgery. J Pak Med A.
2003;53(1):29-32.
5.
Portmann-Lanz CB, Ochsenbein-Kölble N, Marquardt K, et al.
Manufacture of a cell-free amnion matrix scaffold that supports amnion cell
outgrowth in vitro. Placenta. 2007;28(1):6-13.
6.
Niknejad H, Peirovl H, Jorjani M, et al. Properties of the
amniotic membrane for potential use in tissue engineering. Eur Cell Mater.
2008;15:88-99.
[ad_2]